Metabolic Shift Induced by ω -3 PUFAs and Rapamycin Lead to Cancer Cell Death
Background/Aims: Rapamycin (Rp), the main mammalian target of rapamycin complex inhibitor, is a promising therapeutic agent for breast cancer. However, metabolic disorders and drug resistance reduce its efficacy. Epidemiological, clinical, and experimental studies have demonstrated that omega-3 poly...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2018-08-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/492648 |